Remzistotug
Clinical Trials Overview
1 trials found
About Remzistotug
Remzistotug is an experimental monoclonal antibody being developed for the treatment of advanced solid tumors, including colorectal cancer. This agent represents a novel therapeutic approach targeting specific tumor-associated antigens. The drug has entered first-in-human clinical testing for patients with refractory solid malignancies who have exhausted standard treatment options.
Category
Other Medications
Brand Name
Not yet branded
Mechanism
Remzistotug functions as a monoclonal antibody designed to bind to and block specific cell surface receptors or signaling molecules on tumor cells. The exact molecular target and binding mechanism are proprietary, but the agent is designed to either directly inhibit tumor growth or enhance immune system recognition of cancer cells.
1
Total Trials
0
Recruiting
1
Active
0
Completed
152
Total Enrollment
9
Countries
NCT05277051
Phase 1
Active
152 patients
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where ...
United States, Australia, Canada, China, France, Japan, South Korea, Spain, United Kingdom